-
公开(公告)号：EP3116858B1
公开(公告)日：2020-11-11
申请号：EP15760744.1
申请日：2015-03-16
申请人： RaQualia Pharma Inc.
发明人： SHISHIDO, Yuji , OHMI, Masashi , ANDO, Kazuo
IPC分类号： C07D235/02 , A61K31/506 , A61K31/501 , A61K31/4985 , A61K31/498 , A61K31/497 , A61K31/4709 , A61K31/4439 , A61K31/4375 , A61K31/437 , A61K31/427 , A61K31/421 , A61K31/4166 , A61K31/4164 , A61K31/41 , A61P13/02 , A61P11/00 , A61P1/00 , A61P9/10
-
公开(公告)号：EP3632899A1
公开(公告)日：2020-04-08
申请号：EP19210864.5
申请日：2010-05-31
申请人： RaQualia Pharma Inc.
发明人： INOUE, Tadashi , WATANABE, Shuzo , YAMAGISHI, Tatsuya , ARANO, Yoshimasa , MORITA, Mikio , SHIMADA, Kaoru
IPC分类号： C07D213/65 , A61K31/44 , A61K31/443 , A61K31/4433 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K31/4706 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K31/506 , A61P1/00 , A61P1/18 , A61P9/00 , A61P9/06 , A61P13/00 , A61P13/10 , A61P15/00 , A61P19/02 , A61P21/02
摘要： The present invention relates to aryl substituted carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof, which have blocking activities of T-type calcium channels or voltage gated sodium channels as the tetrodotoxin-sensitive (TTX-S) blockers such as Na V1.3 and Na V1.7 , and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels or voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels or voltage gated sodium channels are involved.
-
公开(公告)号：EP2435407B1
公开(公告)日：2019-12-25
申请号：EP10780311.6
申请日：2010-05-31
申请人： RaQualia Pharma Inc.
发明人： INOUE, Tadashi , WATANABE, Shuzo , YAMAGISHI, Tatsuya , ARANO, Yoshimasa , MORITA, Mikio , SHIMADA, Kaoru
IPC分类号： C07D213/65 , A61K31/44 , A61K31/443 , A61K31/4433 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K31/4706 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K31/506 , A61P1/00 , A61P1/18 , A61P9/00 , A61P9/06 , A61P13/00 , A61P13/10 , A61P15/00 , A61P19/02 , A61P21/02
-
公开(公告)号：EP3145926A4
公开(公告)日：2017-12-27
申请号：EP15796887
申请日：2015-05-20
申请人： RAQUALIA PHARMA INC
发明人： NUMATA TOYOHARU , SUDO MASAKI , SUN XUFENG
IPC分类号： C07D413/14 , A61K31/454 , A61P1/04 , A61P1/10 , A61P1/14 , A61P3/10 , A61P9/00 , A61P9/04 , A61P9/06 , A61P11/16 , A61P25/00 , A61P25/06 , A61P25/28 , A61P43/00
CPC分类号： C07D413/14 , A61K31/454
摘要： Salts of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}tetrahydro-2H-pyran-4-carboxylic acid are disclosed. More particularly, salt forms (HCl-salt, HBr-salt, p-toluenesulfonate salt and ethanedisulfonate salt) are disclosed. Furthermore, processes for the preparation of such salt forms, compositions containing such salt forms, and uses of such salt forms are disclosed. A method of treating disease conditions mediated by 5-HT4 receptor activity includes administering an effective amount of such salt forms to an animal, including a human, in need of such treatment.
-
5.发明授权POLYMORPHS OF 4-{[4-({[4-(2,2,2-TRIFLUOROETHOXY)-1,2-BENZISOXAZOL-3-YL]OXY}METHYL)PIPERIDIN-1-YL]METHYL}-TETRAHYDRO-2H-PYRAN-4-CARBOXYLIC ACID AS 5-HYDROXYTRYPTAMINE-4 (5-HT4) RECEPTOR AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISEASES 有权4 - {[4 - （{[4-（2,2,2-三氟乙氧基）-1,2-苯并恶唑-3-基]氧基}甲基）哌啶-1-基]甲基} - 四氢-2H- 吡喃-4-羧酸作为5-羟基硝胺-4（5-HT4）受体激动剂治疗胃肠道疾病
公开(公告)号：EP2922849B1
公开(公告)日：2017-07-12
申请号：EP13856306.9
申请日：2013-11-21
申请人： RaQualia Pharma Inc.
IPC分类号： C07D413/14 , A61K31/454 , A61P1/04 , A61P1/10 , A61P1/14 , A61P3/10 , A61P9/00 , A61P9/04 , A61P9/06 , A61P11/16 , A61P25/00 , A61P25/04 , A61P25/06 , A61P25/28 , A61P43/00
CPC分类号： C07D413/14 , C07B2200/13
-
6.发明授权
公开(公告)号：EP2422779B1
公开(公告)日：2016-01-06
申请号：EP10767106.7
申请日：2010-04-22
申请人： RaQualia Pharma Inc.
IPC分类号： A61K31/192 , A61K31/437 , A61K31/4412 , A61P35/00 , A61P43/00 , C07D213/64 , C07D471/04
CPC分类号： C07D471/04 , A61K31/192 , A61K31/437 , A61K31/44 , A61K31/4412 , A61K45/06 , C07C235/60 , C07D213/82
摘要： This invention provides a medicament for the treatment of cancer, which cause a reduction of cancer. This invention relates to use of a compound which has inhibitory activities against prostaglandin E2 receptor (EP4 receptor) and is represented by the following general formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt for the manufacture of a medicament for the treatment of cancer. The invention relates to a method for treatment of cancer comprising administering the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt to humans or animals. The compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition may be used in combination with one or more second active agents.
-
7.发明公开
公开(公告)号：EP2854810A1
公开(公告)日：2015-04-08
申请号：EP13793644.9
申请日：2013-05-27
申请人： RaQualia Pharma Inc
IPC分类号： A61K31/5025 , A61K31/40 , A61K31/4045 , A61K31/4162 , A61K31/435 , A61K31/454 , A61K31/55 , A61K38/00 , A61P1/04 , A61P1/14
CPC分类号： A61K38/12 , A61K31/395 , A61K31/40 , A61K31/4045 , A61K31/4164 , A61K31/437 , A61K31/444 , A61K31/445 , A61K31/45 , A61K31/454 , A61K31/5025 , A61K38/26 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a use of a compound having ghrelin receptor agonistic activity, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof for the manufacture of a medicament for treatment of diseases including achlorhydria in which abnormal gastric acid secretion is involved. In addition, the present invention relates to the method of treatment including administering to a human or animal. The compound, the pharmaceutically acceptable salt thereof, or pharmaceutical compositions containing them, may be used in combination with one or more second active agents. Further, the present invention relates to pharmaceutical compositions and kits comprising a compound of the present invention or a pharmaceutically acceptable salt thereof for the treatment of said diseases.
-
公开(公告)号：EP2841421A1
公开(公告)日：2015-03-04
申请号：EP13781524.7
申请日：2013-04-25
申请人： RaQualia Pharma Inc
IPC分类号： C07D213/75 , A61K31/44 , A61K31/4523 , A61K31/455 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61P1/00 , A61P25/18 , A61P25/28 , A61P29/00 , A61P43/00 , C07D213/82 , C07D401/04 , C07D401/12
CPC分类号： C07D401/12 , A61K31/44 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4709 , A61K31/501 , A61K31/506 , A61K31/5377 , C07D213/75 , C07D213/81 , C07D213/82 , C07D401/04
摘要： The present invention relates to amide derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.
摘要翻译： 本发明涉及具有电压门控钠通道作为TTX-S通道的阻断活性的酰胺衍生物，其可用于治疗或预防涉及电压门控钠通道的疾病和疾病。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及电压门控钠通道的疾病中的用途。
-
9.发明公开USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES 有权EP4受体拮抗剂的由IL-23介导疾病的治疗中的用途
公开(公告)号：EP2538978A4
公开(公告)日：2013-10-16
申请号：EP11744440
申请日：2011-02-22
申请人： RAQUALIA PHARMA INC
IPC分类号： A61K45/06 , A61K31/381 , A61K31/437 , A61K31/44 , A61K31/4412 , A61K31/443 , A61P1/00 , A61P17/00 , A61P37/00 , A61P37/08 , A61P43/00
CPC分类号： A61K45/06 , A61K31/38 , A61K31/437 , A61K31/44 , A61K31/4412 , A61K31/443 , A61K2300/00
-
公开(公告)号：EP2401268A4
公开(公告)日：2013-01-02
申请号：EP10746028
申请日：2010-03-01
申请人： RAQUALIA PHARMA INC
发明人： SUDO MASAKI , IWATA YASUHIRO , ARANO YOSHIMASA , JINNO MADOKA , OHMI MASASHI , NOGUCHI HIROHIDE
IPC分类号： C07D401/14 , A61K31/454 , A61K31/497 , A61P1/04 , A61P1/06 , A61P43/00 , C07D401/04
CPC分类号： C07D401/04 , C07D401/14
-
-
-
-
-
-
-
-
-
搜索结果
90 条记录 (耗时 0.043 秒)
